Subscribe to our Newsletters !!
Early and accurate pathogen identification is esse
Particle Characterisation Laboratories (PCL) is an
Carrying forward its legacy of advancing the count
BOLTON, Ontario – Husky TechnologiesTM, a pionee
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
Following the success of the promotion and informa
High-performance liquid chromatography (HPLC) digi
Sun Pharmaceutical Industries Limited announced on Thursday that it would purchase Concert Pharmaceuticals of the United States for $576 million in cash in order to gain access to an investigational medication for the treatment of patchy baldness.
Deuruxolitinib, the top contender for Concert, is being studied as a treatment for the autoimmune disorder alopecia areata, which causes patchy hair loss.
Sun Pharma of India said that it will start a tender offer to buy Concert at $8 per share, a premium of 16% over the stock’s most recent finish.
Additionally, contingent value rights will be given to Concert stockholders, entitling them to an extra sum of up to $3.50 per share of common stock in cash, subject to certain sales milestones.
